Page last updated: 2024-12-07

ro 11-2933

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ro 11-2933: analog of tiapamil [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115215
SCHEMBL ID9264045
MeSH IDM0154982

Synonyms (8)

Synonym
1,3-dithiane-2-propanamine, n-(2-(3,4-dimethoxyphenyl)ethyl)-n-methyl-2-(2-naphthalenyl)-
98600-65-8
3,4-dmdp
ro-11-2933
ro 11-2933
n-(3,4-dimethyloxyphenethyl)-n-methyl-2-(2-naphthyl)-1,3-dithiane-2-propylamine
SCHEMBL9264045
DTXSID30243726

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Iatrogenic toxicity resulting from this accumulation of potentially toxic drugs such as CQ within normal cells could complicate the reversal of mdr in vivo."( Reversal of drug-resistant falciparum malaria by calcium antagonists: potential for host cell toxicity.
Grogl, M; Long, GW; Martin, SK; Watt, G,
)
0.13
" D-Verapamil was only about half as toxic as racemic verapamil and this too is consistent with clinical observations."( Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.
Bicknell, SR; Hamilton, T; Kaye, SB; Morrison, JG; Plumb, JA; Setanoians, A; Wishart, GC, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" These effects of DMDP were greater than those of another calcium channel blocker, verapamil, and occurred at one-half the dosage levels."( The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo.
Bankusli, I; Mayhew, E; Radel, S; Rustum, YM, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (18.18)18.7374
1990's9 (81.82)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.30 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]